儿童单次暴露孟鲁司特后不良事件罕见
该研究回顾分析2000–2016年美国国家中毒数据系统中5–17岁儿童单次孟鲁司特暴露记录,共纳入17069例,中位年龄7岁。最常见不良事件为腹痛(0.23%),618例超高剂量(≥50 mg)暴露中腹痛发生率为1.46%。调整年龄和性别后,摄入剂量增加与腹痛相关(调整OR 1.01,95%CI 1.01–1.02)。单次暴露最高达445 mg,未报告严重或危及生命事件,提示儿童单次孟鲁司特过量预后良好。
要点
- 5–17岁儿童单次孟鲁司特暴露17069例中,腹痛是最常见不良事件,发生率0.23%。
- 618例超高剂量(≥50 mg)暴露中腹痛发生率1.46%,仍无严重或危及生命事件。
- 调整年龄和性别后,摄入剂量增加与腹痛相关(调整OR 1.01,95%CI 1.01–1.02)。
- 单次暴露剂量最高达445 mg,未报告严重或危及生命不良事件。
- 该研究为2000–2016年美国国家中毒数据系统回顾性分析,中位年龄7岁,64%为男性。
适用人群与场景
- 5–17岁儿童,因单次孟鲁司特暴露录入美国国家中毒数据系统,且孟鲁司特为原发暴露、摄入剂量为确切或最低可能剂量记录。
- 中位年龄7岁(四分位距5–9岁),64%为男性;超高剂量(≥50 mg)组中位年龄6岁(四分位距5–8岁),56%为男性。
研究设计与关键结果
- 研究类型:美国国家中毒数据系统2000–2016年数据的回顾性分析,纳入17069例5–17岁单次孟鲁司特暴露。
- 不良事件:腹痛最常见,总体发生率0.23%;超高剂量(≥50 mg)组618例中腹痛发生率1.46%。
- 剂量关系:调整年龄和性别后,摄入剂量增加与腹痛相关(调整OR 1.01,95%CI 1.01–1.02)。
- 严重结局:单次暴露剂量最高达445 mg,未报告严重或危及生命事件。
证据类型、等级与局限
- 证据类型:美国国家中毒数据系统数据的回顾性分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,5–17岁儿童单次孟鲁司特暴露剂量最高达445 mg时,不良事件罕见,且与严重或危及生命不良事件无关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
STUDY OBJECTIVE: Montelukast sodium is a leukotriene-receptor antagonist approved as a controller medication for chronic asthma and allergic rhinitis in children and adults. We sought to characterize adverse events associated with single montelukast exposures in children ages 5-17 years and to determine whether adverse events were dose related for all-dose and for ultra-high-dose (≥50 mg) exposures.
METHODS: This is a retrospective analysis of data from the National Poison Data System for exposures that included montelukast in individuals aged 5-17 years for calendar years 2000-2016. Filters were applied to identify exposure events in which montelukast was the primary exposure and for which the exact or lowest-possible ingested dose was recorded. Characteristics of adverse events were examined using descriptive statistics and multivariable logistic models were used to examine whether associations of montelukast and adverse events were dose related.
RESULTS: During the 17-year study period, there were 17,069 montelukast exposures available for analyses. Patients were median [interquartile range] age 7 (5, 9) years, and 10,907 (64%) male gender. Abdominal pain was the most common adverse event (0.23%). There were 618 ultra-high-dose exposures (≥50 mg). These patients had median age 6 (5, 8) years, and 347 (56%) male gender. Abdominal pain was the most common adverse event (1.46%). Increasing ingested dose was associated with abdominal pain (adjusted odds ratio, 1.01, 95% confidence interval 1.01, 1.02) after adjustment for age and gender. No serious or life-threatening events were reported.
CONCLUSIONS: Single-dose exposures of montelukast up to 445 mg are rarely associated with any adverse events and are not associated with serious or life-threatening adverse events in children aged 5-17 years.
参考来源
- Arnold DH, Bowman N, Reiss TF, et al. Adverse events are rare after single-dose montelukast exposures in children. Clin Toxicol (Phila). 2017. PMID: 28639856. doi:10.1080/15563650.2017.1337123
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。